STONY BROOK N.Y., September 25, 2018Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced today that it is launching an additional system to tag the industry’s larger volume cannabis or hemp grows as part of TheraCann International’s ETCH Biotrace™ solution. On the heels of its successful showing of its first Cannabis Tagging System (CTS) in July in San Jose at the NCIA Show, Applied DNA is expanding its cannabis tagging offerings to accommodate different sizes and type of growers in the industry.  The Company’s laboratory services and in-field testing systems round out the solution to support claims of traceability, quality and intellectual properties surrounding a cannabis brand.

“The tremendous interest that came following the show has really accelerated our expansion of tagging solutions to meet the varied cannabis market conditions, including size of grower, indoor, outdoor or hybrid grow, or even the size of plant(s) that justifies the expansion of our tagging equipment solutions,” said Gordon Hope, Director of Cannabis Business Development at Applied DNA Sciences.

The Company’s new design will scale in increments for larger grow operations, enabling these growers an efficient way to tag their cannabis or hemp. The scalable concept utilizes a grow facility’s dry or staging room(s) which can easily be fitted with moveable and expandable POD tagging systems depending upon the size of the room.  The cannabis or hemp present in the room for staging or drying can quickly be tagged without slowing down operations during harvest.

Jason Warnock, CEO of TheraCann International stated, “The expanded portfolio supports and enhances the ETCH Biotrace brand and strategy to offer a comprehensive end-to-end solution to tag, test and track from source to retail shelf.”

ETCH Biotrace combines molecular tagging with TheraCann’s portfolio of licensing, project management, security, cultivation and analysis services.

The Company plans to showcase both the existing CTS design as well as the new POD configuration solution at the upcoming MJBIZCon conference in Las Vegas during the week of November 12, 2018.

APPLIED DNA SCIENCES PROGRAM CONTACT

Gordon Hope
Director, Cannabis Markets
631-240-8850
gordon.hope@adnas.com

INVESTOR CONTACT

Sanjay M. Hurry
LHA Investor Relations
212-838-3777
shurry@lhai.com

MEDIA CONTACT

Cheryl Schneider
DGI Comm
212-825-3210
cschneider@dgicomm.com

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-molecular based “CertainT®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products. SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance, shifting enforcement priorities of US federal laws relating to cannabis, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.